OncLive TV

Naval G. Daver, MD, discusses the advancing treatment landscape in both acute myeloid leukemia and acute lymphoblastic leukemia.

Lucy Gilbert, MD, MSc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Nancy U. Lin, MD, discusses the treatment landscape in HER2-positive metastatic breast cancer. 

Brian Czerniecki, MD, PhD, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.

Naval G. Daver, MD, discusses the utility of maintenance chemotherapy in acute myeloid leukemia.

Brian M. Slomovitz, MD, discusses the role of surgery in women with endometrial cancer.

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents in chronic lymphocytic leukemia.

Kamran A. Ahmed, MD, discusses key strategies to manage patients with breast cancer and brain metastases.

Jason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma. 

Matthew S. Davids, MD, MMSc, discusses the potential utility of ibrutinib in combination with umbralisib in patients with mantle cell lymphoma or relapsed/refractory chronic lymphocytic leukemia.

Sander Bach, MD, PhD, discusses ongoing research with circulating tumor DNA in colorectal cancer.

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.

Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.

Noopur S. Raje, MD, discusses the ​design of the randomized phase 3 E​NDURANCE trial in ​newly diagnosed multiple myeloma.

Sander Bach, MD, PhD, ​discusses ​the results of a systematic review of circulating tumor DNA in colorectal cancer.

Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Luciano J. Costa, MD, PhD, discusses the design of a phase 1 first-in-human study with CC-93269 in relapsed/refractory multiple myeloma.

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Michael J. Morris, MD, discusses the ​design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.